On the other hand, RA patients presented higher percentages of TNFR1+ Th1 and TNFR1+ Th17 cells before, but not after adalimumab treatment, relative to controls (Figure 7B). This evidence concerns the gene TNFRSF1A and rheumatoid arthritis.